Patent intelligence · CA
CA 2712282
COMPOSITION PHARMACEUTIQUE DE DULOXETINE A LIBERATION RETARDEE
COMPOSITION PHARMACEUTIQUE DE DULOXETINE A LIBERATION RETARDEE
Patent details — CA 2712282
- Jurisdiction
- CA
- Status
- granted
- Grant date
- Jul 30, 2009
- Expiration
- Jul 25, 2029
- Applicant
- ALPHAPHARM PTY LTD [AU]
- CPC classes
- A61K 31/ 381 A I, A61K/31381, A61K/92886, A61P 25/ 00 A I
Quick answer
CA 2712282 (COMPOSITION PHARMACEUTIQUE DE DULOXETINE A LIBERATION RETARDEE) is held by ALPHAPHARM PTY LTD [AU]. Status: granted. Granted Jul 30, 2009. Expires Jul 25, 2029 (3 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ALPHAPHARM PTY LTD [AU]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 381 A I, A61K/31381, A61K/92886, A61P 25/ 00 A I, A61P 25/ 02 A I, A61P 25/ 24 A I
Frequently asked questions
What is US patent 2712282?
CA 2712282 (COMPOSITION PHARMACEUTIQUE DE DULOXETINE A LIBERATION RETARDEE) is held by ALPHAPHARM PTY LTD [AU]. Status: granted. Granted Jul 30, 2009. Expires Jul 25, 2029 (3 years remaining) — relevant for patent-cliff and LOE planning.
Who owns CA 2712282?
ALPHAPHARM PTY LTD [AU] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1 pharmaceutical patents for this assignee.
When does CA 2712282 expire?
Our index shows an expiration date of Jul 25, 2029 (3 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.